Tech Center 1600 • Art Units: 1629
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18454315 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 17774002 | SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17599374 | COMPOUNDS AND CONJUGATES THEREOF | Final Rejection | MedImmune Limited |
| 18042931 | METHODS TO PREVENT HIGH-GRADE SEROUS OVARIAN CANCER AND BREAST CANCER BY ADMINISTERING ANTIPROGESTINS | Non-Final OA | The Trustees of Indiana University |
| 18493142 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18267664 | MACROCYCLIC K-RAS G12C INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | Abbisko Therapeutics Co., Ltd. |
| 18041245 | COMBINATION THERAPY | Non-Final OA | Astellas Pharma Inc. |
| 18327213 | ANTIMICROBIAL COMPOUNDS, SYNTHESIS METHODS, AND USES THEREOF | Non-Final OA | Ankh Life Sciences Limited |
| 18263733 | ANTI-VIRAL AGENT | Non-Final OA | NEZU LIFE SCIENCE CO., LTD. |
| 18272939 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | Yanping KONG |
| 17638669 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USED FOR A PATIENT HAVING SPECIFIC GENETIC MARKER | Final Rejection | J-PHARMA CO., LTD. |
| 17638663 | PHENOTHIAZINES AND THEIR DERIVATIVES FOR USE AS A MEDICAMENT | Final Rejection | Guangzhou Virotech Pharmaceutical Co., Ltd. |
| 17637372 | COMPOSITIONS AND METHODS USING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | Non-Final OA | APPLIED BIOLOGICAL LABORATORIES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy